How has been the historical performance of Aurobindo Pharma?

Answer:Aurobindo Pharma has shown a consistent growth trajectory in its historical performance, particularly in net sales and profit metrics over the years leading up to March 2025.

Breakdown:
Aurobindo Pharma's net sales increased from 24,855.38 Cr in March 2023 to 31,723.73 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from 24,855.38 Cr in March 2023 to 31,723.73 Cr in March 2025. The company's operating profit (PBDIT) also saw growth, moving from 4,009.23 Cr in March 2023 to 7,204.64 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose from 2,624.17 Cr in March 2023 to 5,097.98 Cr in March 2025, while profit after tax increased from 1,939.32 Cr to 3,515.26 Cr in the same period. The earnings per share (EPS) improved significantly from 32.9 in March 2023 to 60.02 in March 2025. On the balance sheet, total assets grew from 39,212.50 Cr in March 2023 to 43,858.87 Cr in March 2024, with total liabilities also increasing from 39,212.50 Cr to 43,858.87 Cr. Cash flow from operating activities showed a slight increase from 2,386.00 Cr in March 2023 to 2,434.00 Cr in March 2024, although the net cash inflow/outflow reflected a decrease, moving from 229.00 Cr in March 2023 to -1,006.00 Cr in March 2024. Overall, Aurobindo Pharma's financial performance indicates a robust growth trajectory, particularly in revenue and profitability metrics.